Arkansas is currently home to 732 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Little Rock, Jonesboro, Hot Springs and Fayetteville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis
NCT05177107
Recruiting
This is a phase IIa randomized trial designed to evaluate bacteriophage therapy in patients with diabetic foot osteomyelitis.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
09/05/2023
Locations: Central Arkansas Veteran's Healthcare System, Little Rock, Arkansas
Conditions: Osteomyelitis, Diabetic Foot Osteomyelitis
Register for Updates
Pentoxifylline in Diabetic Kidney Disease
NCT03625648
Recruiting
Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/05/2023
Locations: Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR, Little Rock, Arkansas
Conditions: Diabetic Kidney Disease
Register for Updates
OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages
NCT02523118
Recruiting
The purpose of this observational study is to find the best measures to define how well a person with eosinophilic disorder is doing. People with EoE, EG, EGE and EC normally undergo endoscopy and/or colonoscopy where cells are collected for microscopic analysis. Treatments are then decided based on how the cells look. We are aiming to compare different tissue components such as inflammatory cell types with clinical symptoms. We want to see if scores on standard questionnaires can give us an ide... Read More
Gender:
All
Ages:
3 years and above
Trial Updated:
09/01/2023
Locations: Arkansas Children's Research Institute, Rogers, Arkansas
Conditions: Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis, Eosinophilic Colitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Register for Updates
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490
Recruiting
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by k... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/30/2023
Locations: Mercy Hospital Fort Smith, Fort Smith, Arkansas
Conditions: Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Register for Updates
Effects of Beef Consumption on Skeletal Muscle Protein Homeostasis and Inflammatory Factors in Pre- and Postmenopausal Females
NCT05714462
Recruiting
This will be a randomized study to determine if animal-based protein-rich food sources can stimulate greater muscle protein turnover and whole-body protein balance and reduce skeletal muscle inflammatory markers in postmenopausal women compared to vegetarian base protein-rich foods.
Gender:
Female
Ages:
Between 35 years and 65 years
Trial Updated:
08/29/2023
Locations: Center of Translational Research in Aging and Longevity, Little Rock, Arkansas
Conditions: Menopause Related Conditions
Register for Updates
Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)
NCT04496518
Recruiting
Medtronic is sponsoring the Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS) to further confirm safety and effectiveness of ventricular iATP therapy in routine clinical practice, following commercial release of iATP-capable devices. The iATP PAS is conducted within Medtronic's Product Surveillance Registry platform (NCT01524276).
Gender:
All
Ages:
All
Trial Updated:
08/29/2023
Locations: Cardiology Associates of Northeast Arkansas, Jonesboro, Arkansas
Conditions: Ventricular Tachycardia
Register for Updates
Personalized Therapy Study - HFRS (TriageHF) Post Approval Study
NCT04489225
Recruiting
Medtronic is sponsoring the HFRS PAS to evaluate the HFRS feature (TriageHF) when used in routine clinical practice following commercial release. The HFRS PAS is conducted within Medtronic's Product Surveillance Registry (PSR) platform.
Gender:
All
Ages:
All
Trial Updated:
08/29/2023
Locations: Cardiology Associates of Northeast Arkansas, Jonesboro, Arkansas
Conditions: Heart Failure
Register for Updates
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/28/2023
Locations: Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas
Conditions: Previously Treated Non-Small Cell Lung Cancer
Register for Updates
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
NCT04812925
Recruiting
A Phase 3 study to evaluate the safety and efficacy of efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia
Gender:
All
Ages:
18 years and above
Trial Updated:
08/25/2023
Locations: Investigator Site 0010116, Bentonville, Arkansas
Conditions: Primary Immune Thrombocytopenia
Register for Updates
Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
NCT05912400
Recruiting
Neurofibromatosis type 1 is a common genetic disease with a broad spectrum of clinical manifestations in multiple organs of the body. This project will study the (dys)function of mitochondria in patients with neurofibromatosis through multiple collections of blood samples from patients and people not afflicted by neurofibromatosis (control group). This study will evaluate how the function of mitochondria changes with time and if medications and supplements can influence the function of the mitoc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/23/2023
Locations: University of Arkansas For Medical Sciences, Little Rock, Arkansas
Conditions: Neurofibromatosis 1
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/18/2023
Locations: GSK Investigational Site, Fayetteville, Arkansas
Conditions: Neoplasms
Register for Updates
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
NCT03121586
Recruiting
To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia
Gender:
All
Ages:
18 years and above
Trial Updated:
08/15/2023
Locations: 156-Woodland International Research Group, LLC, Little Rock, Arkansas
Conditions: Schizophrenia
Register for Updates